蛋白酶体抑制剂硼替佐米治疗血液恶性肿瘤的研究

Study of Proteasome Inhibitor Boriezomib in Treatment of Hematologic Malignancies

泛素-蛋白酶体通路是生物体内进行蛋白质选择性降解的重要途径之一,它参与了细胞内许多重要的生理生化过程。蛋白酶体抑制剂可阻断大量调节蛋白的降解,引起细胞内信号系统的紊乱和超负荷,导致细胞生长的抑制,最终使肿瘤进展过程延缓甚至停滞。硼替佐米作为一种蛋白酶体抑制剂,能抑制多发性骨髓瘤细胞的生长及诱导肿瘤细胞的凋亡,同时对血液系统其他恶性肿瘤具有显著作用。本文就蛋白酶体抑制剂硼替佐米治疗血液恶性肿瘤的研究作一综述。

The uhiquitin-proteasome pathway is one of important pathways during protein selective degradation in organism, which participates in many intracellular physiological and biochemical processes. Proteasome inhibitor can block the degradation of quantity of regulatory proteins, result in intracellular signal pathway disorder and over loading, which will result in cell growth inhibition as well as the delay and even stop of tunor invasion. Boriezomib is a kind of proteasome inhibitor, which can inhibit cell growth of multiple myeloma and induce tunor cell apoptosis besides its better effect on the other malignancies of hematological system. This article reviews studies of proteasome inhibitor beriezomib in treatment of hematological malignancies.